Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion type Assertion NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_head.
- NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion description "[Dramatic response has been achieved with EGFR inhibitors (gefitinib and erlotinib) and an ALK inhibitor (crizotinib) in lung cancer expressing corresponding targets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_provenance.
- NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion evidence source_evidence_literature NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_provenance.
- NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion SIO_000772 22435662 NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_provenance.
- NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion wasDerivedFrom befree-20140225 NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_provenance.
- NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_assertion wasGeneratedBy ECO_0000203 NP275388.RAEH2xzThGeQfYB6W-wRbhZjV1pWbrgK34f-H5AgcA77U130_provenance.